203 related articles for article (PubMed ID: 7579354)
1. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
Klumper E; Pieters R; Veerman AJ; Huismans DR; Loonen AH; Hählen K; Kaspers GJ; van Wering ER; Hartmann R; Henze G
Blood; 1995 Nov; 86(10):3861-8. PubMed ID: 7579354
[TBL] [Abstract][Full Text] [Related]
2. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
3. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
4. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
5. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
6. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
7. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
8. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.
Pieters R; Hongo T; Loonen AH; Huismans DR; Broxterman HJ; Hählen K; Veerman AJ
Br J Cancer; 1992 May; 65(5):691-7. PubMed ID: 1350207
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.
Chang WJ; Ko YH; Kim SJ; Kim WS
Leuk Lymphoma; 2014 Sep; 55(9):2196-8. PubMed ID: 24308435
[No Abstract] [Full Text] [Related]
11. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
12. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
13. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
[TBL] [Abstract][Full Text] [Related]
14. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
El-Cheikh J; Moukalled NM; El Darsa H; Massoud R; Kanj SS; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e441-e444. PubMed ID: 30166258
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Zhou K; Song Y; Zhang Y; Wei X; Fu Y; Yu F; Zhou H; Liu X; Zhou J; Fang B
Leuk Res; 2017 Nov; 62():29-33. PubMed ID: 28982056
[TBL] [Abstract][Full Text] [Related]
17. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
18. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Higashigawa M; Hori H; Hirayama M; Kawasaki H; Ido M; Azuma E; Sakurai M
Leuk Res; 1997 Sep; 21(9):811-5. PubMed ID: 9393595
[TBL] [Abstract][Full Text] [Related]
20. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]